Using a blood test to predict rectal cancer treatment success
Part of Cancer, Digestive system clinical trials.
This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have stage II or III rectal cancer that hasn't spread or come back.
- Your doctor is planning to give you total neoadjuvant therapy (chemo and radiation before surgery).
- A sample of your tumor from the initial biopsy is available for testing.
- You agree to participate in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a blood test that finds tumor DNA can help doctors choose the best treatment for rectal cancer, possibly allowing some patients to avoid surgery. It tests different chemotherapy and radiation combinations to see if the cancer disappears completely.
This study looks at whether a genetic test on a small sample of your tumor can predict how well you will respond to chemotherapy and radiation before surgery. This might help doctors choose the best treatment for you.
This trial tests whether checking for tumor DNA in your blood after surgery can help decide if you need additional chemotherapy. If the test finds cancer DNA, you may get chemo to lower the risk of the cancer coming back.
This trial studies lab “biomarkers” (measurable cancer features) to predict whether rectal cancer will resist chemo-radiation before surgery. The goal is to help doctors better choose treatments and avoid ineffective therapy.
This trial tests whether measuring tiny amounts of cancer DNA in the blood before standard treatment can help decide who might safely skip chemotherapy before surgery. It aims to see if a less intensive approach works as well for patients with early rectal cancer.
This study looks at a blood test (ctDNA, a way to detect cancer DNA in the bloodstream) to help doctors choose treatment that may spare organs for people with stage II–III rectal cancer. You may be followed to see how well the blood test can guide treatment decisions.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.